Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001

Inclusion Criteria: * Diagnosis of nHCM * On a stable regimen of guideline-directed medical therapy for nHCM * NYHA functional class II or III * NT-proBNP \>300 pg/mL * Body weight of 50 to 100 kg, inclusive, and BMI ≤40 kg/m2, inclusive * Adequate renal function * Not pregnant, and willing to use acceptable birth control methods * Able and willing to comply with study procedures Exclusion Criteria: * Any evidence of left ventricular outflow tract obstruction (LVOTO) * Implantation of an implantable cardioverter-defibrillator (ICD) within 6 months * History or current evidence of a clinically significant or uncontrolled underlying condition * Unable to tolerate subcutaneous dosing * Any reason that in the opinion of the Investigator would lead to the inability of the participant to comply with the protocol